OSURHIGH SIGNALFINANCIAL10-K

OSUR shows concerning operational performance with gross profit declining 39% despite 30% revenue growth, while R&D expenses increased substantially and cash position weakened significantly.

The combination of contracting gross margins alongside revenue growth suggests either product mix deterioration or rising cost pressures that management has not yet addressed effectively. The substantial increase in R&D spending concurrent with declining profitability indicates the company is investing heavily in future growth while current operations underperform, creating near-term financial pressure.

Comparing 2026-03-09 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

OSUR delivered solid 30% revenue growth but this was overshadowed by a sharp 39% decline in gross profit, indicating significant margin compression. The company substantially increased R&D investments while burning through cash, with cash and equivalents falling 26% to $199M and stockholders' equity declining 17%. The overall financial picture suggests operational challenges are weighing on profitability despite top-line growth, while heavy R&D spending signals management is prioritizing long-term development over near-term margins.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+63.3%
$26.0M$42.5M

R&D investment increased 63.3% — signals commitment to future product development, though near-term margin impact.

Interest Expense
P&L
-45.6%
$316K$172K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Gross Profit
P&L
-39.3%
$79.4M$48.2M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Revenue
P&L
+30.3%
$128.2M$167.1M

Strong top-line growth of 30.3% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
-25.6%
$267.8M$199.3M

Cash decreased 25.6% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-21.4%
$333.2M$261.9M

Current assets declined 21.4% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
+18.9%
$33.5M$39.8M

Current liabilities rose 18.9% — increased short-term obligations, watch current ratio.

Stockholders Equity
Balance Sheet
-16.9%
$410.3M$340.8M

Equity decreased 16.9% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-15.9%
$479.7M$403.2M

Total assets contracted 15.9% — asset sales, write-downs, or balance sheet optimization underway.

Total Liabilities
Balance Sheet
-10.1%
$69.3M$62.3M

Liabilities reduced 10.1% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-07
ADDED
and its wholly owned subsidiaries, and references to "BioMedomics" mean BioMedomics, Inc.
In the United States, the Company owns a number of trademarks, including the OraSure , OTI , OraQuick , OraQuick ADVANCE , ORASURE QUICKFLU , SUREQUICK , InteliSwab , SMART SCIENCE MADE SIMPLE , Oragene , DNA Genotek , OMNImet , ORAcollect , OMNIgene , Diversigen , CoreBiome , Boostershot , MetaGene , Benchmark , Novosanis , Colli-Pee , UCM , UAS , prepIT , NucleoPrecision , ProteoPrecision , HEMAcollect , and HEMAgene trademarks.
OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are.
BioMedomics' SickleSCAN test is the world's first rapid point-of-care test for sickle cell disease.
The SickleSCAN test is currently sold in markets outside the U.S.
+7 more — sign up free →
REMOVED
In the United States, the Company owns a number of trademarks, including the OraSure , Intercept , Intercept i2 he, Intercept i2 he , OraQuick , OraQuick ADVANCE , ORASURE QUICKFLU , SUREQUICK , Q.E.D.
, InteliSwab , Oragene , DNA Genotek , OMNImet , ORAcollect , OMNIgene , Diversigen , CoreBiome , Boostershot , MetaGene , Benchmark , Novosanis , Colli-Pee , UCM , UAS , THINK OUTSIDE THE CUP , AUTO-LYTE , prepIT , and HEMAgene trademarks.
OTI transforms health through actionable insight by powering the shift that connects people to healthcare wherever they are.
In January 2024, the Company completed an equity investment in KKR Sapphiros L.P.
("Sapphiros"), leading its Series B financing and entering into a wide-ranging strategic distribution relationship with Sapphiros, which secures exclusive distribution rights to certain products in Sapphiros' development pipeline, including self-collected blood test and diagnostic tests.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →